Horizon Pharma reports small Q2 profit

Horizon Pharma ($HZNP), which is trying to buy Depomed ($DEPO), today reported a small profit for Q2. It said sales soared 161%, hitting $172.8 million as revenues from newly acquired products kicked in. Horizon has offered $2 billion for Depomed, but Depomed says it has been promised a higher offer from its pursuer. Release | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."